virginiamycin and Haemophilus-Infections

Topics: Anti-Bacterial Agents; Dose-Response Relationship, Drug; Haemophilus Infections; Haemophilus influenzae; Humans; Virginiamycin

Quinupristin/dalfopristin and RPR 106972 were active in vitro against a wide range of aerobic Gram-positive organisms including Enterococcus faecium. However, most isolates of Enterococcus faecalis were resistant or of intermediate sensitivity. Against Staphylococcus aureus quinupristin/dalfopristin was more active but for all other species the range of activity of the two drugs was the same or RPR 106972 was more active. RPR 106972 was also more active against the respiratory pathogens Haemophilus influenzae and Moraxella catarrhalis. Quinupristin/dalfopristin MICs for isolates of H. influenzae (1-8 mg/L) clustered around the breakpoint. There were differences in the quality of growth, but little difference in MICs or zone diameters was obtained on three different media: Mueller-Hinton (MHA), Iso-Sensitest (ISA), and Diagnostic Sensitivity Test (DST) agars. The addition of blood to the medium increased MICs 2- to 4-fold, with MHA showing the greatest increase, and reduced zone diameters around quinupristin/dalfopristin discs by 3-4 mm, with the greatest effect on ISA.

Topics: Anti-Bacterial Agents; Culture Media; Drug Therapy, Combination; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Haemophilus Infections; Haemophilus influenzae; Humans; Microbial Sensitivity Tests; Moraxella catarrhalis; Neisseriaceae Infections; Respiratory Tract Infections; Virginiamycin

Topics: Anti-Bacterial Agents; Drug Resistance, Microbial; Haemophilus Infections; Haemophilus influenzae; Humans; Lung Diseases; Otorhinolaryngologic Diseases; Virginiamycin